The PD-L1 inhibitor avelumab—approved by the FDA in March for the treatment of Merkel cell carcinoma—demonstrated a high number of durable responses in an international, open-label, prospective phase II study. The results of the study, which supported the FDA's decision, were presented in April at the American Association for Cancer Research (AACR) Annual Meeting 2017.
from Cancer via ola Kala on Inoreader http://ift.tt/2qN3G9A
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου